Lexaria Bioscience (LEXX) Income from Continuing Operations (2017 - 2026)
Lexaria Bioscience (LEXX) posted Income from Continuing Operations of 1992981.0 for Q2 2026, down 37.19% sequentially from 1452732.0 in Q1 2026, and up 47.42% YoY from 1351877.85 in Q2 2025.
Lexaria Bioscience (LEXX) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported Income from Continuing Operations for 10 years, with the latest figure at 1992981.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 47.42% year-over-year to 1992981.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was 7729203.0 (up 32.15% YoY) and the FY2025 annual result came in at 25290168.0, down 53.55% from the prior year.
- Income from Continuing Operations fell to 1992981.0 in Q2 2026 per LEXX's latest filing, from 1452732.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 748547.0 in Q3 2022 and troughed at 3790606.0 in Q2 2025.
- A 5-year average of 1969099.44 and a median of 1867387.5 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations plunged 154.23% in 2025, then jumped 47.42% in 2026.
- Over 5 years, Income from Continuing Operations stood at 1741794.0 in 2022, then jumped by 32.38% to 1177848.0 in 2023, then sank by 129.79% to 2706628.0 in 2024, then soared by 40.98% to 1597503.0 in 2025, then declined by 24.76% to 1992981.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1992981.0, 1452732.0, and 1597503.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | -1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -1.99 Mn |
| Feb 28, 2026 | -1.45 Mn |
| Nov 30, 2025 | -1.60 Mn |
| Aug 31, 2025 | -2.69 Mn |
| May 31, 2025 | -3.79 Mn |
| Feb 28, 2025 | -2.72 Mn |
| Nov 30, 2024 | -2.71 Mn |
| Aug 31, 2024 | -2.18 Mn |
| May 31, 2024 | -2.72 Mn |
| Feb 29, 2024 | -1.07 Mn |
| Nov 30, 2023 | -1.18 Mn |
| Aug 31, 2023 | -1.12 Mn |
| May 31, 2023 | -2.40 Mn |
| Feb 28, 2023 | -1.35 Mn |
| Nov 30, 2022 | -1.74 Mn |
| Aug 31, 2022 | -748,547.00 |
| May 31, 2022 | -2.47 Mn |
| Feb 28, 2022 | -1.52 Mn |
| Nov 30, 2021 | -2.09 Mn |
| Aug 31, 2021 | -1.34 Mn |